385 related articles for article (PubMed ID: 33089863)
1. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.
Burke KE; Kochar B; Allegretti JR; Winter RW; Lochhead P; Khalili H; Colizzo FP; Hamilton MJ; Chan WW; Ananthakrishnan AN
Inflamm Bowel Dis; 2021 Jan; 27(2):155-161. PubMed ID: 33089863
[TBL] [Abstract][Full Text] [Related]
2. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
Brenner EJ; Ungaro RC; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
Gastroenterology; 2020 Aug; 159(2):481-491.e3. PubMed ID: 32425234
[TBL] [Abstract][Full Text] [Related]
3. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A
Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry.
Queiroz NSF; Martins CA; Quaresma AB; Hino AAF; Steinwurz F; Ungaro RC; Kotze PG
J Gastroenterol Hepatol; 2021 Nov; 36(11):3033-3040. PubMed ID: 34151470
[TBL] [Abstract][Full Text] [Related]
5. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.
Scucchi L; Neri B; Sarmati L; Mossa M; Sena G; Massoud R; Petruzziello C; Musumeci M; Marafini I; Calabrese E; Lolli E; Bernardini S; Andreoni M; Monteleone G; Biancone L
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2418-2424. PubMed ID: 33755981
[TBL] [Abstract][Full Text] [Related]
6. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 in IBD: The experience of a single tertiary IBD center.
Rizzello F; Calabrese C; Salice M; Calandrini L; Privitera H; Melotti L; Peruzzi G; Dussias N; Belluzzi A; Scaioli E; Decorato A; Siniscalchi A; Filippone E; Laureti S; Rottoli M; Poggioli G; Gionchetti P
Dig Liver Dis; 2021 Mar; 53(3):271-276. PubMed ID: 33451910
[TBL] [Abstract][Full Text] [Related]
8. Humoral response to COVID-19 infection in immunosuppressed patients with inflammatory bowel disease.
Scharrer S; Kutschera M; Weseslindtner L; Primas C; Vogelsang H
Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):443-447. PubMed ID: 33522752
[TBL] [Abstract][Full Text] [Related]
9. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Macaluso FS; Giuliano A; Fries W; Viola A; Abbruzzese A; Cappello M; Giuffrida E; Carrozza L; Privitera AC; Magnano A; Ferracane C; Scalisi G; Minissale MG; Giangreco E; Garufi S; Bertolami C; Cucinotta U; Graziano F; Casà A; Renna S; Teresi G; Rizzuto G; Mannino M; Maida M; Orlando A
Inflamm Bowel Dis; 2023 Feb; 29(2):217-221. PubMed ID: 35385102
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients With Inflammatory Bowel Diseases.
Kochar B; Cai W; Cagan A; Ananthakrishnan AN
Gastroenterology; 2020 Jun; 158(8):2104-2111.e2. PubMed ID: 32105728
[TBL] [Abstract][Full Text] [Related]
11. Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group.
Arrigo S; Alvisi P; Banzato C; Bramuzzo M; Celano R; Civitelli F; D'Arcangelo G; Dilillo A; Dipasquale V; Felici E; Fuoti M; Gatti S; Knafelz D; Lionetti P; Mario F; Marseglia A; Martelossi S; Moretti C; Norsa L; Panceri R; Renzo S; Romano C; Romeo E; Strisciuglio C; Martinelli M
Dig Liver Dis; 2021 Mar; 53(3):283-288. PubMed ID: 33388247
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease.
Wetwittayakhlang P; Albader F; Golovics PA; Hahn GD; Bessissow T; Bitton A; Afif W; Wild G; Lakatos PL
Can J Gastroenterol Hepatol; 2021; 2021():7591141. PubMed ID: 34858891
[TBL] [Abstract][Full Text] [Related]
13. Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases.
Singh S; Heien HC; Sangaralingham L; Shah ND; Sandborn WJ
Clin Transl Gastroenterol; 2021 Jul; 12(7):e00380. PubMed ID: 34228004
[TBL] [Abstract][Full Text] [Related]
14. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic.
El Ouali S; Rubin DT; Cohen BL; Regueiro MD; Rieder F
Curr Opin Gastroenterol; 2021 Jul; 37(4):313-319. PubMed ID: 33859104
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications.
Khan N; Mahmud N
Gastroenterology; 2021 Sep; 161(3):827-836. PubMed ID: 34048782
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of pneumonia among patients with inflammatory bowel disease.
Long MD; Martin C; Sandler RS; Kappelman MD
Am J Gastroenterol; 2013 Feb; 108(2):240-8. PubMed ID: 23295276
[TBL] [Abstract][Full Text] [Related]
17. Safety of biologics in inflammatory bowel disease patients with COVID-19.
Weissman S; Aziz M; Smith WL; Elias S; Swaminath A; Feuerstein JD
Int J Colorectal Dis; 2021 Sep; 36(9):2051-2055. PubMed ID: 34131784
[TBL] [Abstract][Full Text] [Related]
18. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease.
Sahyoun LC; Fetene J; McMillan C; Protiva P; Al Bawardy B; Gaidos JKJ; Proctor D
Dig Dis Sci; 2024 May; 69(5):1654-1660. PubMed ID: 38466459
[TBL] [Abstract][Full Text] [Related]
19. Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic.
Moum KM; Moum B; Opheim R
Scand J Gastroenterol; 2021 May; 56(5):545-551. PubMed ID: 33771086
[TBL] [Abstract][Full Text] [Related]
20. Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease Under Biologic Treatment.
Norsa L; Cosimo P; Indriolo A; Sansotta N; D'Antiga L; Callegaro A
Gastroenterology; 2020 Dec; 159(6):2229-2231.e2. PubMed ID: 32860790
[No Abstract] [Full Text] [Related]
[Next] [New Search]
